Malignant transformation in a Breast Adenomyoepithelioma Caused by Amplification of c-MYC : A Common pathway to Cancer in a Rare Entity

Journal of breast cancer
Christopher A Febres-AldanaRobert Poppiti

Abstract

Breast adenomyoepitheliomas are composed of a biphasic proliferation of myoepithelial cells around small epithelial-lined spaces. Due to the rarity of adenomyoepitheliomas, the molecular data describing them are limited. Adenomyoepitheliomas are considered to be benign or have low malignant potential, and be prone to local recurrence. Malignant transformation has been associated with homozygous deletion of CDKN2A or somatic mutations in TERT, but remains unexplained in many cases. Here, we describe a case of carcinomatous transformation of both epithelial and myoepithelial cells in an estrogen receptor-negative adenomyoepithelioma caused by amplification of MYC. Break-apart fluorescence in situ hybridization revealed an increase in the MYC gene copy number (3-4 copies/cell in 37%, > 4 copies/cell in 40%). Deregulation of MYC is responsible for uncontrolled proliferation and cellular immortalization in basal-like breast cancers. Our case demonstrates that genomic instability events associated with gene amplification may be involved in the carcinogenesis of malignant adenomyoepitheliomas.

References

Mar 21, 1998·Virchows Archiv : an International Journal of Pathology·S A Rasbridge, R R Millis
Oct 13, 1998·Virchows Archiv : an International Journal of Pathology·G Seifert
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tatyana A GrushkoOlufunmilayo I Olopade
Sep 15, 2005·The American Journal of Surgical Pathology·Bernadette K McLarenDavid L Page
Jul 28, 2007·Cancer Genetics and Cytogenetics·Sigríthur K BodvarsdóttirJorunn E Eyfjörd
Jul 23, 2011·Genes & Cancer·Jinhua XuOlufunmilayo I Olopade
Dec 27, 2018·International Journal of Surgical Pathology·Jordan E BaumPaula S Ginter

❮ Previous
Next ❯

Citations

Apr 9, 2021·Histopathology·Emad RakhaCecily Quinn
Oct 19, 2020·Current Cancer Drug Targets·Milad AshrafizadehManoj Garg

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.